Summary
Bristol-Myers Squibb Company (BMY) reported strong performance in its 2009 10-K filing, demonstrating revenue growth driven by key pharmaceutical products such as PLAVIX* and ABILIFY*, alongside significant expansion in its virology and immunology portfolios. The company continued its strategic transformation into a biopharmaceutical company through divestitures of non-core businesses, like Mead Johnson, and strategic "string-of-pearls" acquisitions, notably Medarex. This transformation, coupled with a productivity initiative, aimed at improving efficiency and cost management, positions BMY for future growth. While facing the ongoing challenge of generic competition, particularly impacting PLAVIX* in European markets, BMY highlighted robust sales growth for newer products like BARACLUDE, SUSTIVA Franchise, ABILIFY*, and ORENCIA. The company also reported progress in its R&D pipeline, with key investigational compounds like belatacept and dapagliflozin advancing through clinical trials, indicating a focus on innovation. Investors can look to BMY's continued execution of its biopharmaceutical strategy, pipeline development, and management of product exclusivity as key factors influencing future performance.
Financial Highlights
59 data points| Revenue | $18.81B |
| Cost of Revenue | $5.14B |
| Gross Profit | $13.67B |
| R&D Expenses | $3.65B |
| SG&A Expenses | $3.95B |
| Operating Expenses | $13.21B |
| Operating Income | $3.24B |
| Interest Expense | $184.00M |
| Net Income | $10.61B |
| EPS (Basic) | $5.35 |
| EPS (Diluted) | $5.34 |
| Shares Outstanding (Basic) | 1.97B |
| Shares Outstanding (Diluted) | 1.98B |
Key Highlights
- 1Net sales increased by 6% to $18.8 billion in 2009, driven by strong performance in key products like PLAVIX* (up 10%) and ABILIFY* (up 20%).
- 2The company continued its strategic transformation by divesting the Mead Johnson Nutrition Company and executing "string-of-pearls" acquisitions, such as Medarex, to focus on its biopharmaceutical core.
- 3Significant sales growth was reported in the virology portfolio, with BARACLUDE up 36% and the SUSTIVA Franchise up 11%, while ABILIFY* saw a 20% increase.
- 4BMY is actively managing its product portfolio and intellectual property, with an eye on upcoming patent expirations and generic competition, particularly noting the impact on PLAVIX* sales in Europe.
- 5Research and development spending remained substantial at $3.6 billion in 2009, supporting a pipeline with promising compounds in areas like transplantation (belatacept) and diabetes (dapagliflozin).
- 6The company's financial position remained strong, with cash, cash equivalents, and marketable securities totaling $9.9 billion at year-end 2009, supported by significant cash flow from operations.
- 7BMY is focusing on emerging markets, identifying Brazil, Russia, India, China, and Turkey as key growth opportunities aligned with its innovation-focused strategy.